AI-Generated Filing Summaries

Amendment dated March 31, 2026 modifies the January 13, 2026 MOU with Innovest S.p.A. and BP4 S.r.l. in liquidazione — clarifies consent/blockage rights related to BP4’s 11.31% stake in Milestone.

‘Qualified Offering’ is redefined as a securities offering within 45 days of March 31, 2026 generating at least $900,000 in gross proceeds and up to 19.99% of outstanding shares — enabling near-term financing.

Lock-up deadline extended from January 31, 2026 to April 17, 2026 (or May 1, 2026 if a Qualified Offering is actively underway) — delays share restrictions for BP4 Parties and insiders.

Issued unregistered Shares including 958,857 Series II Anchor I Shares for $9,914,833 and 1,212,663 Series II Anchor II Shares for $12,507,462 on March 2, 2026.

Net Asset Value per share as of February 28, 2026 ranged from $10.21 to $10.39 across Series I and II classes.

Total Net Asset Value stood at $397,075 thousand with 38,405,587 outstanding shares as of February 28, 2026.

Entered binding Term Sheet dated March 23-27, 2026, superseding January 2025 version.

Vaximm grants BCME exclusive worldwide sublicensable license to develop and commercialize VXM01 for all indications.

BCME Fund pays up to $815M milestones directly to OSRH upon clinical, regulatory, commercial achievements.

Entered binding Term Sheet dated March 23-27, 2026, superseding January 2025 version.

Vaximm grants BCME exclusive worldwide sublicensable license to develop and commercialize VXM01 for all indications.

BCME Fund pays up to $815M milestones directly to OSRH upon clinical, regulatory, commercial achievements.

Annual shareholder meeting scheduled for Thursday, June 25, 2026.

Record date for notice and voting: Friday, May 1, 2026.

Beneficial ownership determination date: Friday, May 1, 2026.

Earnings release for quarter ended March 31, 2026, to be issued after close on April 20, 2026.

Investor presentation and materials posted to https://home24bank.investorroom.com.

Conference call scheduled for 10:30 a.m. CDT on April 21, 2026.

Othership partnered with Achieve Engagement, gaining access to a network of 35,000 HR and talent leaders to offer workplace scheduling solutions.

Othership partnered with ScaleHR, providing its workplace intelligence solution to ScaleHR's network of over 30,000 HR leaders and practitioners.

DeskFlex launched in Brazil, marking its expansion into Latin America and adding Brazilian Portuguese language support to its platform.

Entered Stock Exchange Agreement on March 26, 2026, with CEO Lourdes Felix, President Louis C Lucido, and Director Kent Emry.

Shareholders transferred 1,215 Subsidiary shares (12.15% ownership) for 2,263,371 restricted Parent Shares.

Exchange closed March 27, 2026, as part of Plan of Reorganization approved February 25, 2026.

KBRA affirmed Corporation's senior unsecured debt rating of BBB+, subordinated debt rating of BBB, and short-term debt rating of K2.

KBRA affirmed Bank's deposit rating of A-, senior unsecured debt rating of A-, subordinated debt rating of BBB+, and short-term ratings of K2.

Ratings affirmation signals stable credit profile for both entities.

Board appointed Ed Dermit on February 11, 2026, as independent director and Audit Committee member with 25 years financial leadership.

Board appointed Jason Goss on February 11, 2026, bringing 22+ years oil & gas operations experience.

Board appointed J.P. Dick on March 25, 2026, with 43+ years petroleum engineering and reserves evaluation expertise.

Acquisition of three exploration properties—Guibord (50%), Marriott (100%), and Holloway (100%)—for C$2.5 million in cash, enhancing land position adjacent to the Fenn-Gib Project.

Guibord property is contiguous to Fenn-Gib concessions, 5 km southwest of the deposit, and provides highway access and key land for permitting infrastructure.

All properties lie along or near the Porcupine-Destor Fault Zone, a regionally significant structure with >180M oz historical gold production and >300M oz estimated endowment.

Revolving credit facility commitments increased to $740 million, with $254.8 million outstanding as of March 30, 2026.

A new $235 million Incremental Term A-1 Loan Facility was added solely to fund the Thermon Group Holdings acquisition.

Net leverage ratio covenant stepped up to 4.50x post-acquisition, declining to 4.00x after five quarters.

Justin Earl resigned from the Board of Directors effective immediately on April 1, 2026.

Resignation not due to any disagreement on operations, policies, or practices.

Daniel Schmidt appointed as director effective immediately to fill the vacancy.

Optical display tech company outsourcing production to OEMs like Wuxi Sharp, generating $26.2M revenue FY2025 (140% YoY growth) but $1.8M net loss.

Offering 4M Class A shares at $4-5/share for ~$15.8M net proceeds (60% R&D, 10% marketing, 30% working capital); Nasdaq 'BLTG'.

Dual-class structure: CEO Senlin Chen controls 89% voting power post-IPO via 12.7M Class B shares.

Amendments executed March 5, 2026, effective January 1, 2026 with 11 noteholders.

Extended maturity of $490,000 9.5% secured convertible notes and $50,000 unsecured convertible notes to Dec 31, 2026.

Waived all defaults on notes through effective date.

Entered $176M floating-rate non-recourse loan on March 27, 2026, secured by four properties, completing $634M term loan refinance.

Loan terms: SOFR + 410 bps, 5-year term with two 1-year extensions, interest-only.

Refinancing with prior $425M financing extends maturities to 2031, reduces debt by >$33M, boosts annual free cash flow by >$30M.

Andy Cheung appointed EVP and CFO effective April 20, 2026, succeeding Rebecca Thompson.

Rebecca Thompson transitions from CFO to Chief Accounting Officer on April 20, 2026.

Luke Bomer joins as General Counsel effective April 1, 2026, after serving as outside counsel.

AIGC became controlling shareholder holding 65.1% of Moolec Science SA's outstanding shares on April 1, 2026.

Conversion effected pursuant to Subscription Agreement dated December 9, 2024, as amended June 16, 2025, between Bioceres Group Limited and AIGC.

Transaction followed business combination making Bioceres Group Limited a subsidiary of the Company.

AIGC became controlling shareholder holding 65.1% of Moolec Science SA's outstanding shares on April 1, 2026.

Conversion effected pursuant to Subscription Agreement dated December 9, 2024, as amended June 16, 2025, between Bioceres Group Limited and AIGC.

Transaction followed business combination making Bioceres Group Limited a subsidiary of the Company.

PDMRs including CEO Tadeu Marroco received 64 ordinary shares each at £43.71 under Share Reward Scheme (most recipients), totaling £2,797.44 per award.

Pascale Meulemeester and David Waterfield received 21 and 64 shares respectively under International Share Reward Scheme at £43.71.

Select PDMRs purchased 3-4 shares each at £43.88507 via Partnership Share Scheme on London Stock Exchange.

PDMRs including CEO Tadeu Marroco received 64 ordinary shares each at £43.71 under Share Reward Scheme (most recipients), totaling £2,797.44 per award.

Pascale Meulemeester and David Waterfield received 21 and 64 shares respectively under International Share Reward Scheme at £43.71.

Select PDMRs purchased 3-4 shares each at £43.88507 via Partnership Share Scheme on London Stock Exchange.

Nexstar Media Inc. issued $1,725 million in 7.250% Senior Notes due 2034 in a private offering exempt from registration.

Proceeds will fund the redemption of the issuer's 5.625% Senior Notes due 2027 and pay related fees and expenses.

The notes are guaranteed on a senior unsecured basis by Nexstar Media Group, Inc., Mission Broadcasting, Inc., and certain other subsidiaries.

Reallocation of February liquidation proceeds caused $4,688,541.72 additional principal to Class A-M Certificateholders.

February distribution overpaid interest by $1,240,984.97 to Class C and $3,447,556.81 to Class D Certificateholders.

March distribution impacted with $18,437.37 additional interest to Class B Certificateholders.

Early-stage biotech with Revealia Breast test using proprietary mRNA biomarkers; plans Q1 2026 launch but no revenue generated yet.

Offering 1,670,379 Common Units at $8.98/unit (1 share + 1 Warrant exercisable at $11.23/share, 5-year term); net proceeds ~$13.55M.

Use of proceeds: $6.43M research/clinical studies, $4.28M sales/marketing, $1.09M debt repayment, $1M G&A, $0.75M working capital.

Motoko Imada appointed CEO to oversee operations, P&L, and comprehensive business/cost structure review.

Joey Chung transitions from CEO to President, focusing on corporate development, strategic transactions, and investor relations.

2026 initiatives target organic revenue growth, positive EBITDA, and SG&A reduction as % of revenue.

The Bank committed to issue or assume $4.325 billion in consolidated obligations, including $2.25 billion in short-term variable-rate discount notes maturing July 2026 — highlighting near-term funding activity.

New fixed-rate bonds include a $15 million 3.88% note maturing March 2029 and a $10 million 5.70% note maturing April 2041 — reflecting issuance across the yield curve.

Multiple callable structures are reported: American, Bermudan, and Optional Principal Redemption provisions — indicating embedded prepayment flexibility and interest rate risk management.

Issued 2,150 Series D shares for $1M gross proceeds in private placement on March 27, 2026.

Settled $7.583M promissory note with 7,583 Series D shares and $684K notes with 684 Series E shares.

Series D and E convertible at $0.10/share after 1-year hold (Series D) or immediately (Series E), with 12-month down-round adjustment.

James D. Farley, Jr. was elected to McDonald's Board of Directors effective February 4, 2026 — adds independent director with automotive and operational leadership experience.

Mr. Farley was appointed to the Audit & Finance Committee and Corporate Responsibility Committee on March 30, 2026 — expands board oversight capacity in financial governance and ESG-related matters.

The appointments reflect ongoing board refreshment and alignment with evolving corporate governance expectations for large-cap consumer companies.

Revenue grew 8.9% year-over-year to $78.4 million, driven by positive impacts from sales volume and price, which management highlights as a key focus area for evaluating performance.

Gross profit increased 6.7% to $41.5 million, with a gross margin of 52.9%, as the company benefited from pricing and volume dynamics that positively impacted margin.

Operating loss deepened by 29.8% to -$13.0 million, and net loss widened by 83.4% to -$8.1 million, indicating that revenue gains were overshadowed by significant expense pressures.

CWCapital Asset Management LLC was terminated as special servicer for The Veranda and Audubon Crossings & Commons loan combinations effective April 2, 2025.

Torchlight Loan Services, LLC was appointed as the successor special servicer for the affected loan combinations under the BMARK 2021-B30 PSA.

LMCG Investments, LLC, as Directing Holder, executed the termination and appointment pursuant to Sections 3.22(b) and 7.02 of the PSA.